How does 761's PE Ratio compare to its peers?

761 is good value based on its Price-To-Earnings Ratio (31.9x) compared to the peer average (32.2x).

How does 761's PE Ratio compare vs other companies in the European Personal Products Industry?

761 is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the European Personal Products industry average (23.8x).

What is 761's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

761 is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the estimated Fair Price-To-Earnings Ratio (18.5x).

What is the Fair Price of 761 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

761 (€54.3) is trading above our estimate of [[fair value]] (€42.86)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

761 Stock Overview

A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. More details

761 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	6/6
Financial Health	5/6
Dividends	2/6

Rewards

Earnings are forecast to grow 18.48% per year

Earnings grew by 36.3% over the past year

Analysts in good agreement that stock price will rise by 56.2%

Risk Analysis

No risks detected for 761 from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Pharmanutra S.p.A. Competitors

Beiersdorf

XTRA:BEI

€27.6b

MTG

TSE:7806

JP¥68.4b

Warpaint London

AIM:W7L

UK£429.2m

Liuzhou Liangmianzhen

SHSE:600249

CN¥2.9b

Price History & Performance

Summary of share price highs, lows and changes for Pharmanutra
Historical stock prices
Current Share Price	€54.30
52 Week High	€63.10
52 Week Low	€45.00
Beta	0.33
1 Month Change	-0.55%
3 Month Change	-6.86%
1 Year Change	-5.07%
3 Year Change	-26.62%
5 Year Change	n/a
Change since IPO	46.76%

Recent updates

Shareholder Returns

	761	DE Personal Products	DE Market
7D	1.3%	-1.5%	-1.6%
1Y	-5.1%	-7.2%	6.8%

Return vs Industry: 761 exceeded the German Personal Products industry which returned -7.6% over the past year.

Return vs Market: 761 underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is 761's price volatile compared to industry and market?
761 volatility
761 Average Weekly Movement	3.2%
Personal Products Industry Average Movement	3.7%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 761 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 761's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2003	119	Roberto Lacorte	www.pharmanutra.it

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company’s products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, Cetilar Nutrition, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2.

Pharmanutra S.p.A. Fundamentals Summary

How do Pharmanutra's earnings and revenue compare to its market cap?
761 fundamental statistics
Market cap	€518.83m
Earnings (TTM)	€16.27m
Revenue (TTM)	€113.13m

31.9x

P/E Ratio

4.6x

P/S Ratio

Is 761 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
761 income statement (TTM)
Revenue	€113.13m
Cost of Revenue	€56.03m
Gross Profit	€57.09m
Other Expenses	€40.82m
Earnings	€16.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 14, 2025

Earnings per share (EPS)	1.69
Gross Margin	50.47%
Net Profit Margin	14.38%
Debt/Equity Ratio	39.6%

How did 761 perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

50%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 14:47
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmanutra S.p.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andrea Randone	Intermonte SIM S.p.A.
Giorgio Tavolini	Intermonte SIM S.p.A.
Daniele Alibrandi	Stifel, Equities Research